Edwards Lifesciences Corporation $EW Shares Sold by Baxter Bros Inc.

Key Points

• Baxter Bros Inc. reduced its holdings in Edwards Lifesciences Corporation by 36.3%, selling 28,075 shares in the second quarter, bringing their total ownership to 49,161 shares valued at approximately $3.845 million.
• Wall Street analysts have issued positive ratings for Edwards Lifesciences, with several firms raising their target prices, indicating a general consensus of a "Moderate Buy" with an average target price of $87.06.
• Insider transactions saw VP Daniel J. Lippis and insider Larry L. Wood selling shares recently, reducing their individual holdings by 15.75% and 4.15%, respectively.

Baxter Bros Inc. lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 36.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,161 shares of the medical research company's stock after selling 28,075 shares during the quarter. Baxter Bros Inc.'s holdings in Edwards Lifesciences were worth $3,845,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $1,760,000. Czech National Bank lifted its holdings in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock worth $11,214,000 after purchasing an additional 7,917 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, Dynamic Advisor Solutions LLC lifted its holdings in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Royal Bank Of Canada lifted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. William Blair raised Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Finally, Piper Sandler lifted their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $87.06.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 1.3%

Shares of NYSE:EW opened at $75.75 on Thursday. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00. The company has a market capitalization of $44.47 billion, a PE ratio of 10.90, a PEG ratio of 3.69 and a beta of 1.05. The business has a 50 day moving average of $78.28 and a two-hundred day moving average of $76.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the company posted $0.70 earnings per share. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.